SCHEMBL890511

SCHEMBL890511

Cc1ccccc1-c1cc(=O)n2ccccc2n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.49
METTL3 Q86U44 3/20 0.48
KDM4E B2RXH2 2/20 0.45
ADORA3 P0DMS8 2/20 0.45
ADORA2A P29274 1/20 0.45
ADORA2B P29275 1/20 0.45
ADORA1 P30542 1/20 0.45
PRKDC P78527 1/20 0.45
DRD4 P21917 1/20 0.44
DRD3 P35462 1/20 0.44
HSP90AA1 P07900 1/20 0.44
HSP90AB1 P08238 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
FLT1 P17948 1/20 0.43
CDK8 P49336 1/20 0.43
CDK9 P50750 1/20 0.43
LIMK1 P53667 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32688213 0.82 GRIN1 (0.48) METTL3KDM4EMAPTHPGDKMT2A
SCHEMBL7920089 0.81 HSP90AA1 (0.49) KDM4EADORA3ADORA1HSP90AA1HSP90AB1
SCHEMBL16379086 0.81 METTL3 (0.44) METTL3KDM4EADORA3ADORA1KMT2A
SCHEMBL8102203 0.81 HSP90AA1 (0.47) METTL3KDM4EADORA3ADORA2AADORA2B
SCHEMBL1659994 0.78 KDM4E (0.52) KDM4EADORA3ADORA2AADORA2BADORA1
SCHEMBL2823070 0.77 KDM4E (0.64) KDM4EADORA3ADORA2AADORA2BADORA1
SCHEMBL8105559 0.77 RAB9A (0.54) METTL3KDM4EADORA3ADORA2AADORA2B
SCHEMBL890730 0.74 GRM5 (0.54) KDM4EADORA3ADORA2AADORA2BADORA1
SCHEMBL1834856 0.74 ADORA3 (0.47) KDM4EADORA3ADORA2AADORA2BADORA1
SCHEMBL8099804 0.73 RAB9A (0.49) KDM4EADORA3ADORA2AADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754089-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-06-17 US disclosed
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 DPP4 4491/4885METTL3 4699/4885KDM4E 1436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.